Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years.
Jagadeswara Rao Earla +5 more
doaj +1 more source
Frontiers in Neuroscience, 2021 Favorable effects exerted by long-term administration of fingolimod therapy in multiple sclerosis (MS) patients have been reported, but sporadic side effects, such as reversible macular edema, also have been recorded. The present study aimed to determine
Tao Yang +8 more
doaj +1 more source
A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. [PDF]
, 2020 Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited.
A Haghikia +20 more
core +1 more source
Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
Antibiotics, 2022 The aim of this study was to determine whether fingolimod could synergize the antibacterial activity of doripenem against carbapenem-resistant Escherichia coli (CREC) and its potential as an antibiotic adjuvant for doripenem. The E.
Hye-Won Jin, Hye-Rim Kim, Yong-Bin Eom
doaj +1 more source
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]
, 2020 Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola +4 more
core +1 more source
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. [PDF]
, 2014 BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis.
Blanc, Caroline A +2 more
core +1 more source
Sphingosine 1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis? [PDF]
, 2017 Sphingosine 1-phosphate (S1P) is a bioactive lipid that is characterized by a peculiar mechanism of action. In fact, S1P, which is produced inside the cell, can act as an intracellular mediator, whereas after its export outside the cell, it can act as ...
Frati, Alessia +4 more
core +2 more sources
Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin [PDF]
BioImpacts, 2023 Introduction: Fingolimod is a drug that is used to treat multiple sclerosis (MS). It has pH-dependent solubility and low solubility when buffering agents are present.
Samira Gholizadeh +5 more
doaj +1 more source
BMC Neurology, 2017 Background Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse.
Anat Achiron +7 more
doaj +1 more source
Fingolimod phosphate protection against mitochondrial damage in neuronal cells [PDF]
, 2019 Background: Major role of oxidative stress in the pathogenesis of neurodegenerative diseases have been suggested, being mitochondria one of the main sources of ROS. Aim: In the present work, we have studied the antioxidant effect of fingolimod phosphate
Alvarez-Gil, Antonio +8 more
core +1 more source